

IELSG

INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP

TRIALS COORDINATION CENTRE: ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND

OSPEDALE SAN GIOVANNI CH-6500 BELLINZONA - SWITZERLAND

E. ZUCCA, A. CONCONI, S. GRISANTI, F. CAVALLI / C. MORININI, M. TROVESI

PHONE ++41 91 820 91 11 - FAX ++41 91 820 91 82 - E-MAIL ielsg@ticino.com

NEWSLETTER 10

Bellinzona, December 2001

1. NEW PROPOSALS

A MULTICENTRIC RANDOMIZED TRIAL OF CHLORAMBUCIL VS CHLORAMBUCIL PLUS RITUXIMAB IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA

This study is intended to be the natural evolution of the IELSG 3 & 6 trials. All the MALT lymphoma patients with localised disease at any site who do not respond to local therapy, the H. pylori-negative gastric lymphomas or those who failed antibiotic therapy will be eligible as well as those with disseminated or multifocal disease.

Single agent chemotherapy with chlorambucil has been shown to be active in MALT lymphomas and is widely accepted as a standard therapy for disseminated low-grade lymphomas. Since the very favourable natural history of most MALT lymphoma and the advanced age of many patients we do believe that a more aggressive regimen would not be appropriate in the standard arm. Furthermore, there is a rationale for combining Rituximab with chemotherapy, since the mechanisms of action are distinct and there is also evidence that rituximab may sensitize chemoresistant tumor cells to the actions of cytotoxic drugs.

General design: after randomization the patient is assigned to either:

- arm A: CLB for 6 months (given as in the LY03/IELSG3 study)
- arm B: CLB + Rituximab

(the optimal design to be discussed after a feasibility study of the combination which is ongoing in Bellinzona and Milan).

Hopefully this study will be officially activated during the next Lymphoma Conference in Lugano, June 2002. Discussion is open for comments.

2. NEW ENTRIES

IELSG 17 MULTI- INSTITUTIONAL RETROSPECTIVE ANALYSIS OF INTRAVASCULAR LYMPHOMATOSIS

- The protocol has already been activated in August 2001.
- Instructions for data collection can be obtained either directly from the Chairmen (ferreri.andres@hsr.it) or from IELSG (ielsg@ticino.com).
- A central pathological review will be performed.
- Chairmen: *A. Ferreri and M. Ponzoni, Milan, Italy.*

IELSG 18 RETROSPECTIVE INTERNATIONAL SURVEY ON PRIMARY EFFUSION LYMPHOMAS

- The protocol will be activated by January 2002.
- Forms are intended to be filled and sent as attached documents by e-mail. Histological reports must be faxed or sent by mail as usual.
- A central pathological review will be performed.
- For contacts: *A. Conconi, Novara, Italy (conconi@med.unipmn.it)*, *A. Carbone, Aviano, Italy (acarbonate@cro.it)*.

3. ONGOING STUDIES AND ACCRUALS

IELSG 4 PROSPECTIVE RANDOMIZED TRIAL OF CHEMOTHERAPY VS CHEMOTHERAPY PLUS IRRADIATION IN DIFFUSE LARGE- CELL GASTRIC LYMPHOMAS

ACCRUAL	pts 37
- Instituto de Enfermedades Neoplasticas, Lima, Peru	18
- Istituto Europeo di Oncologia, Milano, Italy	11
- Casa di Cura G.B. Mangioni, Lecco, Italy	3
- Ospedali Riuniti, Bergamo, Italy	2
- Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy	1
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy	1
- Oncology Institute of Southern Switzerland	1

IELSG 10 PROSPECTIVE TRIAL IN DIFFUSE LARGE- CELL TESTICULAR LYMPHOMAS

ACCRUAL	pts 7
- Ospedale Maggiore S. Giovanni Battista, Torino, Italy	2
- Ospedale Infermi, Rimini, Italy	1
- Instituto de Enfermedades Neoplasticas, Lima, Peru	1
- Oncology Institute of Southern Switzerland	1
- Istituto Clinico Humanitas, Milano, Italy	1
- Spedali Civili, Brescia, Italy	1

IELSG 11 RETROSPECTIVE EVALUATION OF CUTANEOUS B- CELL LYMPHOMAS

ACCRUAL	pts 192
- Ospedali Riuniti, Bergamo, Italy	60
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy	36
- Istituto Europeo di Oncologia, Milano, Italy	17
- Ospedale Umberto I, Mestre, Italy	15
- Ospedale di Circolo Fondazione Macchi, Varese, Italy	12
- Peter MacCallum Cancer Institute, East Melbourne, Australia	12
- Ospedale San Raffaele, Milano, Italy	11
- Ospedale di Belluno, Italy	9
- Oncology Institute of Southern Switzerland	7
- Ospedale Ramazzini di Carpi, Italy	5
- Ospedale S. Bortolo, Vicenza, Italy	3
- Ospedale Regionale Ca'foncello, Treviso, Italy	3
- Spedali Riuniti Santa Chiara, Pisa, Italy	2

IELSG 14 RETROSPECTIVE EVALUATION OF PRIMARY BONE LYMPHOMA

IELSG 15 RETROSPECTIVE EVALUATION OF PRIMARY BREAST LYMPHOMA

IELSG 16 RT- PCR DETECTION OF THE t(11;18) TRANSLOCATION AS A PREDICTOR OF OUTCOME IN EXTRANODAL MARGINAL LYMPHOMA OF MALT TYPE

These trials have just been activated and no accrual is available yet.

Data collection from each study will be centralised at the IELSG Trials Coordination Centre, unless differently specified.

All protocols and forms will be provided upon request to ielsg@ticino.com.

4. PUBLICATIONS

"Molecular follow-up in gastric MALT lymphomas: early analysis from the LY03 cooperative trial." *F. Bertoni, A. Conconi, C. Capella, T. Motta, R. Giardini, M. Ponzoni, E. Pedrinis, D. Novero, P. Rinaldi, G. Cazzaniga, A. Biondi, A. Wotherspoon, B. Hancock, P. Smith, R. Souhami, F. Cotter, F. Cavalli, E. Zucca for the IELSG and the UKLG.*

Accepted for publication on "Blood"

5. IELSG AGENDA

ASH 2001

ORAL PRESENTATION (IELSG 3)

"Gastric MALT Lymphomas Prospective LY03 Randomised Cooperative Trial: Preliminary Results of the Molecular Follow-Up." *Francesco Bertoni, Annarita Conconi, Carlo Capella, Teresio Motta, Roberto Giardini, Maurilio Ponzoni, Ennio Pedrinis, Domenico Novero, Paolo Rinaldi, Giovanni Cazzaniga, Andrea Biondi, Andrew Wotherspoon, Barry W. Hancock, Robert Souhami, Paul Smith, Finbarr E. Cotter, Franco Cavalli, Emanuele Zucca.*

Date/Time: Monday, December 10, 2001 2:15 PM Location: Hall F-4

ORAL PRESENTATION (IELSG 6)

"Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT-Type)." *Annarita Conconi, Catherine Thiéblemont, Giovanni Martinelli, Andrés J. M. Ferreri, Liliana Devizzi, Fedro Peccatori, Maurilio Ponzoni, Virginio Filipazzi, Pierre-Yves Dietrich, Massimo A. Gianni, Franco Cavalli, Emanuele Zucca (Intr. by Franco Cavalli).*

Date/Time: Monday, December 10, 2001 4:45 PM Location: Hall F-4

POSTER SESSION (IELSG 11)

"Prognostic Scoring System for Primary Cutaneous B-Cell Lymphoma (PCBCL)." *Sergio Cortelazzo, Teresio Motta, Andrea Rossi, Elena Oldani, Liliana Devizzi, Mario Busetto, Andrés J.M. Ferreri, Giovanni Martinelli, Miles H. Prince, Graziella Pinotti, Annarita Conconi, Franco Cavalli, Tiziano Barbui.*

Date/Time: Sunday, December 09, 2001 10:00 AM Location: Hall C, Poster Board Number 543

NEXT IELSG MEETING

It will be held in **Lugano**, Switzerland during the 8th International Conference on Malignant Lymphomas, on **Saturday, June 15, 2002** at the **Palazzo dei Congressi** (approximately from 1:00 pm to 5:00 pm)

IELSG Office will be closed from December 22, 01 to January 7, 02. For special communications please e-mail us.

To you all the best wishes for a Merry Christmas and a lucky 2002!

E. Zucca, S. Grisanti, F. Cavalli, C. Morinini, M. Trovesi